TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04580134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clozapine
Description: Biotype 1 and Biotype 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clozapine
Description: Biotype 1 and Biotype 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: risperidone
Description: Biotype 1 and Biotype 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: risperidone
Description: Biotype 1 and Biotype 2
Study: NCT05778968

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low etco2
Description: Etco2 levels will be adjusted at levels ranging between 25 mm Hg and 30 mm Hg
Study: NCT04620291

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421 SC
Description: The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421 SC
Description: The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.
Study: NCT05778968

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: normal etco2
Description: Etco2 levels will be adjusted at levels ranging between 31 mm Hg and 40 mm Hg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high etco2
Description: Etco2 levels will be adjusted at levels ranging between 41 mm Hg and 45 mm Hg
Study: NCT04620291

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421 SC
Description: The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421 SC
Description: The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421 SC
Description: The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.
Study: NCT04431193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin infused to maintain serum concentrations of 4, 16, 64, and 256 picogram/millilitre

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin infused to maintain serum concentrations of 4, 16, 64, and 256 picogram/millilitre

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin infused to maintain serum concentrations of 4, 16, 64, and 256 picogram/millilitre

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin infused to maintain serum concentrations of 4, 16, 64, and 256 picogram/millilitre
Study: NCT05738187

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local cryotherapy treatment
Description: cryotherapy
Study: NCT05039372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAINING AND CONSULTANCY
Description: TRAINING AND CONSULTANCY
Study: NCT05408806

Intervention type: OTHER
Intervention: Exercise Interventions
Description: Rehabilitation methods and exercise practices to improve postural control in children with cerebral palsy. In addition to neurodevelopmental treatment, one group is treated with virtual reality games and the other group is treated with a hippotherapy simulator.

Intervention type: OTHER
Intervention: Exercise Interventions
Description: Rehabilitation methods and exercise practices to improve postural control in children with cerebral palsy. In addition to neurodevelopmental treatment, one group is treated with virtual reality games and the other group is treated with a hippotherapy simulator.
Study: NCT05883072

Intervention type: BEHAVIORAL
Intervention: Exploring AI-Chatbot
Description: All participants will be provided access to AI-Chatbot and will be asked to enquire their daily life problems related to diabetes. They will also be asked to review the replies of the Chatbot after their interaction.
Study: NCT05347979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Dabigatran will be administered orally as a 75 mg capsule on Day 1 and Day 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant
Description: Relacorilant will be administered orally as 4 X 100 mg capsules (400 mg) on Days 3 through 13.
Study: NCT06276270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucopad HA
Description: The product is a Class III Medical Device incorporating a medicinal substance (antiseptics-octenidine) within the composition made of sodium hyaluronate polysacharide stabilised by calcium chloride. Device is administered directly onto the area affected by mucositis.
Study: NCT05639790

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Electronic cigarettes + Health Counselling
Description: Ad libitum use of electronic cigarettes for 1 month

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Health Counselling
Description: Health Counselling from a licensed mental health counselor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Counselling
Description: Health Counselling from a licensed mental health counselor
Study: NCT05711537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular Acupressure with Vaccaria 600t ear seeds
Description: Auricular Acupressure utilizing vaccaria 600 t ear seeds applied to 5 designated sites to each ear. Both ears will have seeds applied. Participants will be asked if they consent to having their intervention session photographed and audio recorded in collaboration with the BAA press training and intervention fidelity study.
Study: NCT05279625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exercise training
Description: using either elastic band, dumbbells, treadmill, cycling, machines for 6 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exercise training
Description: using either elastic band, dumbbells, treadmill, cycling, machines for 6 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exercise training
Description: using either elastic band, dumbbells, treadmill, cycling, machines for 6 months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: using either elastic band, dumbbells, treadmill, cycling, machines for 6 months
Study: NCT06437379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infection control
Description: To evaluate the effect of implementing teaching protocol on nurse's knowledge and practice regarding infection control measures for patients undergoing Percutaneous Nephrolithotomy.
Study: NCT05025969

Intervention type: OTHER
Intervention: Glioma data collection
Description: Glioma data collection

Intervention type: OTHER
Intervention: Brain metastasis data collection
Description: Brain metastasis data collection
Study: NCT06215014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric handgrip training
Description: Participants will train three days per week at home for 1 month using a reliable and validated digital handgrip dynamometer (DynX, MD System, Inc., Westerville, USA) in a seated position. The isometric handgrip training protocol will consist of four sets (2 for each hand) of two-min sustained contractions starting at 30% of maximum voluntary contraction (MVC) interspersed by 1-min resting periods (a total of 12-min). All training sessions will be remotely supervised via Zoom or phone call by a research team member to ensure compliance with the exercise prescription. Before each training session, MVCs will be re-assessed over three repetitions, each separated by 30-s, to ensure an accurate exercise prescription. The highest value will be used to determine the target intensity of the session
Study: NCT05741684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioral Therapy
Description: iCBT was administered in an unguided fashion without human therapeutic support. Participants were instructed to progress through the eight core modules over an 8-week period. The modules comprised psychoeducational content centered around CBT, aimed at promoting the development of skills such as self-monitoring of emotions, cognitive distancing, cognitive reframing/restructuring, problem-solving, and mindfulness. In the event of technical difficulties during the intervention, participants were able to seek assistance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: The Dot-Probe Paradigm was utilized within the Attention Bias Modification procedure. The training sessions were comprised of 96 trials, which included facial expression photos depicting happiness, neutrality, and sadness, sourced from four male and four female actors. A fixed cross (+) was presented on the computer screen's center for a duration of 500 milliseconds before each stimulus display, followed by the presentation of two images portraying distinct emotional expressions, which persisted for 500 milliseconds. After the disappearance of the images, an arrow appeared in the location where they had been displayed, and participants were instructed to select the arrow that corresponded with the presented arrow. In the ABM procedure, the arrow was consistently presented following the display of a more positive facial expression, such that in the instance of a sad-neutral face pair, the arrow would always appear in the location of the neutral facial expression image.
Study: NCT05563298

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuro RX Gamma device
Description: The Neuro RX Gamma device is a portable, wearable, low level light therapy (LLLT) delivery device. The Vielight Neuro RX Gamma delivers a synchronized pulse frequency of 40 Hz from all LED clusters.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Neuro RX Gamma device
Description: The Sham device is indistinguishable from the active device. The sham device will not deliver light for the 20 minutes session duration.
Study: NCT05628428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise to strengthen neck area.
Description: An exercise protocol will be carried out through educational videos. There will be a total of four videos which will pose exercises for two weeks each. These exercises will be done twice a week. A reminder will be sent by email on the days that they must be carried out.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information
Description: Information will be provided on neck pain and how exercise is able to help prevent it.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information
Description: Information will be provided on neck pain and how exercise is able to help prevent it.
Study: NCT05038644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb18968 - Dose level -1
Description: 0.1 mg IV C1D1, 0.3 mg IV C1D2, then 0.4 mg IV on D8, D15, and D22 in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb18968 - Dose level -1
Description: 0.1 mg IV C1D1, 0.3 mg IV C1D2, then 0.4 mg IV on D8, D15, and D22 in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb18968 - Dose level 0 (starting dose)
Description: 0.2 mg IV C1D1, 0.6 mg IV C1D2, then 0.8 mg IV on D8, D15, and D22 in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb18968 - Dose level 0 (starting dose)
Description: 0.2 mg IV C1D1, 0.6 mg IV C1D2, then 0.8 mg IV on D8, D15, and D22 in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb18968 - Dose level 1
Description: 0.25 mg IV C1D1, 0.75 mg IV C1D2, then 1.0 mg IV on D8, D15, and D22 in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb18968 - Dose level 1
Description: 0.25 mg IV C1D1, 0.75 mg IV C1D2, then 1.0 mg IV on D8, D15, and D22 in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb18968 - Dose level 2
Description: 0.4 mg IV C1D1, 0.9 mg IV C1D2, then 1.3 mg IV on D8, D15, and D22 in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb18968 - Dose level 2
Description: 0.4 mg IV C1D1, 0.9 mg IV C1D2, then 1.3 mg IV on D8, D15, and D22 in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb18968 - Dose level 3
Description: 0.5 mg IV C1D1, 1.0 mg IV C1D2, then 1.5 mg IV on D8, D15, and D22 in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb18968 - Dose level 3
Description: 0.5 mg IV C1D1, 1.0 mg IV C1D2, then 1.5 mg IV on D8, D15, and D22 in a 28-day cycle.
Study: NCT06229002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial alternative current stimulation (tACS) at alpha frequency
Description: Single session of tACS

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Description: Single session of tACS sham stimulation
Study: NCT06530745

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid (HA) injection
Description: 2% hyaluronic acid Synocrom Forte (Croma-Pharma GmbH, Leobendorf, Austria) injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Description: PRP from peripheral venous blood of the elbow bend centrifuged at 160 revolutions per minute for 5 minutes with iFuge D06 (Neuation Technologies Pvt. Ltd, Gujarat, India) injection
Study: NCT06364605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation with the iReach novel multisensory medical device
Description: From the results of Phases 1,2 and 3, in Phase 4 a medical device for spatial and sensorimotor rehabilitation in infants aged 3 to 36 months will be tested and developed.
Study: NCT05924711

Intervention type: OTHER
Intervention: Retrospective analysis of demographic and radiographic data previously obtained from the patient.
Description: The patient's demographic data obtained previously by anamnesis and clinical examination will be retrospectively analyzsed. On the other hand, a radiographic evaluation including analysis of the implants, adjacent teeth and maxillary sinuses/sinus membranes shall be performed using computer software.

Intervention type: OTHER
Intervention: Retrospective analysis of demographic and radiographic data previously obtained from the patient.
Description: The patient's demographic data obtained previously by anamnesis and clinical examination will be retrospectively analyzsed. On the other hand, a radiographic evaluation including analysis of the implants, adjacent teeth and maxillary sinuses/sinus membranes shall be performed using computer software.
Study: NCT05316675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: isotretinoin 13-cis-retinoic acid), derived from vitamin A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: isotretinoin 13-cis-retinoic acid), derived from vitamin A
Study: NCT05508230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic Nasal Spray
Description: Health care product - nasal application
Study: NCT06193265

Intervention type: PROCEDURE
Intervention: Discectomy
Description: Discectomy is total or more often partial intervertebral disc surgical removal

Intervention type: PROCEDURE
Intervention: Discectomy
Description: Discectomy is total or more often partial intervertebral disc surgical removal
Study: NCT05353998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDS with Sleep Navigation
Description: The Sleep Navigation program will involve 1-3 meetings between the Sleep Navigator (SN) and the participating family. Participants will also complete baseline and post-intervention assessments, and about 10 to 15 caregivers will be randomly invited to participate in an interview on the acceptability and feasibility of the program. The SN will provide: SDB and sleep health psychoeducation using Patient-Family Education handouts and videos that are currently part of usual care practices; Care coordination for scheduling of specialty care referral(s) for clinical SDB evaluation; Problem-solving for family-identified barriers to accessing specialty care; and Motivational interviewing to enhance family engagement, communication, and collaboration with the family's medical team.

Intervention type: OTHER
Group type: OTHER
Intervention: CDS-only
Description: Participants will complete baseline and post-intervention assessments. Participants will be able to follow-up with their primary care clinician as needed.
Study: NCT06579027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPEED Training
Description: Children will use ride-on toys controlled using their affected arm to navigate through their environment and complete playful theme-based challenges. Children will use their affected UE during navigation to start and stop the toy, move steadily forward and backward, turn to the right and left, perform 180° and 360° turns to either side, and avoid obstacles. Children will complete object-based UE tasks requiring gross and fine motor control at intermediate stops during navigation. Navigational tasks will be progressed by increasing complexity of paths (straight to slalom paths needing more directional changes), spaces (wide to narrow spaces), and precision (obstacle courses and mazes requiring skillful navigation, motor planning, and route finding). Object-based tasks will be progressed in terms of force requirements (small to large forces), range of motion (near to far reaches), precision (manipulation of large to small objects), and speed of movements (slow to fast).
Study: NCT04648579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hillrom
Description: Hillrom Connecta solution will record vital signs in an automated way, without the need for human intervention, and activate TRR activation when at least one criteria is met. The frequency of monitoring vital signs will be defined based on the MEWS score.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Hospital usual care regarding vital signs collection and TRR activation.
Study: NCT06067711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: resistance band
Description: The program will consist of six exercises: triceps press, biceps curl, lat pull down, leg press, leg extension and sit-ups using resistance band.
Study: NCT06389305

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: peripheral blood lymphocytes
Description: autologous or allogeneic peripheral blood lymphocytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIK cell
Description: autologous or allogeneic cytokine-induced killer (CIK) cells
Study: NCT06579027

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CRAFT Training
Description: Children will engage in predominantly seated activities based on conventional occupational therapy to promote unimanual and bimanual UE function. Training sessions will be based on playful child-friendly themes (e.g., dinosaurs, space exploration, aquatic theme, etc.) and all training activities will incorporate the session theme. Activities will involve practice of functional gross and fine motor UE movement patterns that children typically use during daily life. Training will emphasize the use of the affected UE in different roles (i.e., stabilizer, mobilizer, and active and passive assist) during warm-up, building, and art-craft activities. The training will be progressed in terms of forces needed, range of motion, precision, and movement speed.
Study: NCT05691257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: The initial dose of roxadustat was given according to body weight, which was more than 60kg: 100mg (three times a week); Weight less than 60kg: 70mg (three times a week); 2 weeks later, the corresponding indexes were rechecked and medication was adjusted according to hemoglobin. The target is hemoglobin 100-120g/L.~Reference for medication Method: The use of roxadustat is the same as the RCT study of roxadustat in the treatment of anemia and the drug instructions of roxadustat published by N Engl J Med in 2019.

Intervention type: DRUG
Group type: OTHER
Intervention: Recombinant human eythropoietin and/or Iron agents
Description: Other drugs to treat anemia include: Recombinant human eythropoietin (RH-EPO), iron agents (ferrous succinate, polysaccharide iron complex, iron sucrose, etc.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human eythropoietin and/or Iron agents
Description: Other drugs to treat anemia include: Recombinant human eythropoietin (RH-EPO), iron agents (ferrous succinate, polysaccharide iron complex, iron sucrose, etc.)
Study: NCT04802941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy by CDSS (MedicBK)
Description: CDSS (MedicBK) captures the patient-specific data required to determine appropriate care decisions from the EMR and then presents relevant data alongside treatment suggestions to clinicians. MedicBK uses algorithms for presenting treatment suggestions framed by guideline-based therapy and personalized personalized evidence-based therapy. MedicBK consists of three main blocks: database, network meta-analysis, and heterogeneity of treatment effects assessment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General practice
Description: General practice
Study: NCT06057376

Intervention type: OTHER
Group type: OTHER
Intervention: Low-FODMAP diet group (LFD)
Description: Each participant will be following a low-FODMAP diet group for 3 weeks, followed by 3 week break prior to second diet intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Low Sugar diet group (LAS)
Description: Each participant will be following a low added sugar diet group for 3 weeks, after 3 week break.